Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"HitGen","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Has Successfully Completed a Three-Year Collaboration With MTPC to Discover Novel Hit Compounds for Multiple Drug Targets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"HitGen"}]

HitGen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

HitGen Has Successfully Completed a Three-Year Collaboration With MTPC to Discover Novel Hit Compounds for Multiple Drug Targets

Details:

During the three-year collaboration, multiple undisclosed targets (including undruggable targets) were screened against HitGen’s proprietary DNA encoded chemical libraries (DELs). The majority of the targets have resulted in confirmed novel potent hits.

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Mitsubishi Tanabe Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 25, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY